It wasn’t just media news that caused supplement companies to start trying to find hoodia gordonii supplies. Press releases by Phytopharm, a British pharmaceutical company, about researching hoodia and negative effects that might be related to hoodia caused the original stir in the health supplement industry.
Phytopharm has two operating divisions; a plant extract division and a pharmaceutical division. In June of 1997, Phytopharm announced that “a naturally occurring appetite suppressant is to be progressed into a prescription medicine by Phytopharm “.This was to be Phytopharm’s hoodia gordonii product. News of a naturally occurring appetite suppressant sent, not just supplement companies, but people who needed to lose weight searching for this “naturally occurring appetite suppressant “.In those days, everyone expected Phytopharm’s hoodia gordonii product to be a prescription drug though it was consistently referred to by the business as a “natural anti-obesity treatment “.Their collaboration with Pfizer, another pharmaceutical company, to analyze hoodia and negative effects that might be due to hoodia use only supported the idea that Phytopharm’s hoodia gordonii would have been a prescription drug. Now, since they have partnered with Unilever, not just a pharmaceutical company, it’s somewhat unclear what Phytopharm’s hoodia gordonii product will be. They do seem focused on the idea that Phytopharm’s hoodia gordonii is going to be better than products that are still on the market.
Phytopharm’s product development strategy begins in what they call “proof of principle” clinical testing. These tests are made to determine in case a product has the potential to be safe and effective. Uganda Proof principle testing of Phytopharm’s hoodia gordonii product began in March of 2001. News about hoodia and negative effects were released next first phase was completed in December of 2001. This was a naturally occurring substance and there appeared to be no negative effects associated using its use. After completing the original clinical testing, Phytopharm’s strategy advances to the search for a partner company for “late stage development, sales and marketing “.The partner company for Phytopharm’s hoodia gordonii product is Unilever, manufacturers of food products, dietary supplements and non-prescription medications. Among their more famous products is “Slim Fast “.Phytopharm is still researching and investigating the chance or perhaps a drug to treat metabolic disorder and hoodia gordonii is the basis for this drug.
Phytopharm attempts to acquire patents for naturally occurring substances. “Phytopica” is just a Phytopharm product for treating dermatitis in dogs and was just released in April of 2006. Phytopharm’s hoodia gordonii product is patented, but they have had more than a little trouble keeping other manufacturers of natural products from selling their very own hoodia products. In May of 2006, they announced that they certainly were conscious that others were selling hoodia gordonii as an appetite suppressant and which they thought that this could be patent infringement. They said that they’d contacted the right authorities. The problem is that a naturally occurring product can’t be patented. If Phytopharm’s hoodia gordonii product is unique and therefore stronger, safer and better compared to the hoodia products that are still on the market, then how could there be patent infringement and why would they take into account companies that are selling what they imply are inferior products?
There is no comparison between the known side aftereffects of hoodia and negative effects related to appetite suppressants which contain stimulants. Products which contain both hoodia and stimulants could produce a problem. It’s thought that problems with Ephedra arose consequently to be combined with caffeine and other stimulants. The problem was that this can not be proven without endangering human health. Hopefully, Phytopharm’s hoodia gordonii product is going to be stimulant free as are lots of the hoodia products that are still on the market.